0
Es befinden sich keine Waren im Warenkorb !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Start > GP120

GP120

Brief Information

Name:Transmembrane protein PVRIG
Target Synonym:PVRIG,PVR Related Immunoglobulin Domain Containing,CD112 Receptor,Poliovirus Receptor-Related Immunoglobulin Domain-Containing Protein,Poliovirus Receptor Related Immunoglobulin Domain Containing,Nectin-2 Receptor,C7orf15,CD112R,Transmembrane Protein PVRIG,MGC2463
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:7
Lastest Research Phase:Phase 2 Clinical

Product ListCompare or Buy

ACRO Quality

Part of Bioactivity data

GP4-V15223-ELISA
 GP120 ELISA

Immobilized Human CD4, Fc Tag (Cat. No. CD4-H5259) at 5 μg/mL (100 μL/well) can bind HIV-1 [HIV-1/Clade E (CM244)] GP120, His Tag (Cat. No. GP4-V15223) with a linear range of 20-156 ng/mL (QC tested).

GP4-V15227-MALS-HPLC
GP120 MALS images

The purity of HIV-1 [HIV-1/Clade B/C (CN54)] GP120, His Tag (Cat. No. GP4-V15227) is more than 90% and the molecular weight of this protein is around 90-120 kDa verified by SEC-MALS.

Synonym Name

GP120,GP120-CN54

Background

Human Immunodeficiency Virus (HIV) can be divided into two major types, HIV type 1 (HIV-1) and HIV type 2 (HIV-2). HIV-1 is related to viruses found in chimpanzees and gorillas living in western Africa. HIV-2 is related to viruses found in sooty mangabeys. HIV-1 viruses may be further divided into groups. The HIV-1 group M viruses predominate and are responsible for the AIDS pandemic. Some of the HIV-1 group M subtypes are known to be more virulent or are resistant to different medications. HIV-2 viruses are thought to be less virulent and transmissible than HIV-1 M group viruses. Envelope glycoprotein GP120 (or gp120) is the name of the glycoprotein which forms the spikes sticking out of a HIV virus particle. gp120 is essential for virus entry into cells as it plays a vital role in seeking out specific cell surface receptors for entry. Three gp120s, bound as heterodimers to a transmembrane glycoprotein, gp41, are thought to combine in a trimer to form the envelope spike, which is involved in virus-cell attachment. One half of the molecular weight of gp120 is due to the carbohydrate side chains (the "glyco-" in "glycoprotein"). These are sugar residues which form something almost like a sugar "dome" over the gp120 spikes. This dome prevents gp120 from being recognised by the human immune response. As the HIV virus and the human CD4 cell come together, the gp120 binding site "snaps open" at the last minute.The glycoprotein gp120 is anchored to the viral membrane, or envelope, via non-covalent bonds with the transmembrane glycoprotein, gp41. It is involved in entry into cells by binding to CD4 receptors, particularly helper T-cells. Binding to CD4 is mainly electrostatic although there are van der Waals interactions and hydrogen bonds.

Clinical and Translational Updates

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
SIM-0348 SIM-0348 Phase 1 Clinical Simcere Pharmaceutical Group Ltd Solid tumours; Neoplasms Details
PM-1009 PM1009 Phase 1 Clinical Biotheus Inc Solid tumours; Neoplasms; Lung Neoplasms Details
COM-701 COM-701 Phase 2 Clinical Compugen Ltd Ovarian Neoplasms; Head and Neck Neoplasms; Solid tumours; Triple Negative Breast Neoplasms; Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Endometrial Neoplasms; Lung Neoplasms Details
NM1F NM1F; TGI-2 Phase 1 Clinical Hefei TG ImmunoPharma Co Ltd Ovarian Neoplasms; Solid tumours; Triple Negative Breast Neoplasms; Colorectal Neoplasms; Melanoma Details
SHR-2002 SHR-2002 Phase 1 Clinical Suzhou Suncadia Biopharmaceuticals Co Ltd, Shanghai Hengrui Pharmaceutical Co Ltd Neoplasms Details
JS-009 JS-009; TAB009 Phase 1 Clinical Shanghai Junshi Biosciences Co Ltd Solid tumours; Neoplasms Details
GSK-4381562 SRF-813; GSK-4381562 Phase 1 Clinical Surface Oncology Inc Neoplasms Details
SIM-0348 SIM-0348 Phase 1 Clinical Simcere Pharmaceutical Group Ltd Solid tumours; Neoplasms Details
PM-1009 PM1009 Phase 1 Clinical Biotheus Inc Solid tumours; Neoplasms; Lung Neoplasms Details
COM-701 COM-701 Phase 2 Clinical Compugen Ltd Ovarian Neoplasms; Head and Neck Neoplasms; Solid tumours; Triple Negative Breast Neoplasms; Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Endometrial Neoplasms; Lung Neoplasms Details
NM1F NM1F; TGI-2 Phase 1 Clinical Hefei TG ImmunoPharma Co Ltd Ovarian Neoplasms; Solid tumours; Triple Negative Breast Neoplasms; Colorectal Neoplasms; Melanoma Details
SHR-2002 SHR-2002 Phase 1 Clinical Suzhou Suncadia Biopharmaceuticals Co Ltd, Shanghai Hengrui Pharmaceutical Co Ltd Neoplasms Details
JS-009 JS-009; TAB009 Phase 1 Clinical Shanghai Junshi Biosciences Co Ltd Solid tumours; Neoplasms Details
GSK-4381562 SRF-813; GSK-4381562 Phase 1 Clinical Surface Oncology Inc Neoplasms Details

This web search service is supported by Google Inc.

totop
Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
Fax
Fax
+1 888-377-6111
Address
Address
Lichtstrasse 35,4056 Basel, Switzerland

Nachricht schicken